Elanco Animal Health (NYSE:ELAN) Announces Earnings Results

Elanco Animal Health (NYSE:ELAN - Get Free Report) posted its earnings results on Tuesday. The company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01), Zacks reports. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.08 earnings per share.

Elanco Animal Health Trading Up 2.4 %

NYSE:ELAN traded up $0.27 during midday trading on Friday, hitting $11.19. 6,902,175 shares of the company traded hands, compared to its average volume of 4,960,017. The firm's fifty day moving average is $11.71 and its 200-day moving average is $13.03. Elanco Animal Health has a 12-month low of $10.20 and a 12-month high of $18.80. The firm has a market capitalization of $5.53 billion, a P/E ratio of 27.96, a P/E/G ratio of 2.50 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Wall Street Analysts Forecast Growth

ELAN has been the subject of a number of research reports. Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday. Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Leerink Partnrs upgraded Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Finally, UBS Group decreased their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has an average rating of "Hold" and a consensus target price of $15.83.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.